title: Pregnant with metastatic neuroendocrine tumour of the ovary: what now?
abstract: Neuroendocrine tumours (NET) are a heterogeneous group of neoplasms commonly occurring in the gastrointestinal tract or lungs but can occur in other regions. Primary ovarian NET account for 5% of all NET and 0.1% of all ovarian malignancies. In metastatic disease, the therapeutic goal is to extend survival and to improve quality of life. As these tumours express somatostatin receptors, somatostatin analogues are frequently used to control symptoms. Here we present a case of a pregnant woman with an ovarian NET with liver metastases and carcinoid syndrome who was treated with the somatostatin analogue, Octreotide LAR. We also summarize reported data of the use of somatostatin analogues during pregnancy.
authors.affiliation: Department of Medical Oncology, Ospedale di Macerata and Fertility and Procreation in Oncology Unit, Department of Medicine, European Institute of Oncology, Milan, Italy.
authors.forename: B
authors.initials: B
authors.lastname: Pistilli
authors.forename: Cm
authors.initials: C
authors.lastname: Grana
authors.forename: N
authors.initials: N
authors.lastname: Fazio
authors.forename: A
authors.initials: A
authors.lastname: Cavaliere
authors.forename: Me
authors.initials: M
authors.lastname: Ferrari
authors.forename: L
authors.initials: L
authors.lastname: Bodei
authors.forename: Sm
authors.initials: S
authors.lastname: Baio
authors.forename: G
authors.initials: G
authors.lastname: Scambia
authors.forename: G
authors.initials: G
authors.lastname: Paganelli
authors.forename: Fa
authors.initials: F
authors.lastname: Peccatori